Saturday 17 October 2026
Export ALZN’s income statement to Excel — free account
Alzamend Neuro, Inc.
ALZN Healthcare Biotechnology
In the quarter to July 2026, EPS grew 46.9% and free cash flow grew 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.32
0.04
+3.13%
Follow ALZN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 2,524.50 | 661.50 | 75.78 | 9.54 | 1.69 | 0.84 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | 45,292.50 | 3,294.00 | 1,071.90 | 135.54 | 11.70 | 2.54 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 6 | 6 | 8 | 7 | 7 | 7 | 6 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EBT | — | (5) | (4) | (4) | (5) | (12) | (15) | (10) | (5) | (9) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | 0 | 0 | 0 | (4) | (5) | (12) | (15) | (10) | (5) | (9) | |||||
| Depreciation | — | — | 0 | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | (0.01) | (111.51) | (83.52) | (93.74) | (188.92) | (202.42) | (132.31) | (11.32) | (2.63) | |||||
| Cash flow | — | (0.02) | (23.97) | (44.43) | (50.41) | (100.21) | (123.59) | (111.46) | (14.57) | (2.42) | |||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | (1.61) | 0.00 | (1.98) | (0.67) | 0.00 | |||||
| Free cash flow | — | (0.02) | (23.97) | (44.43) | (50.41) | (101.83) | (123.59) | (113.44) | (15.24) | (2.42) | |||||
| Book value | — | 0.00 | 0.00 | 15.56 | 37.41 | 202.30 | 42.18 | (34.96) | 8.80 | 0.22 | |||||
| Shares, m | — | 85 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (2) | (1) | (2) | (3) | (7) | (9) | (8) | (7) | (8) | ||||
| Capex | — | — | — | — | — | 0 | — | 0 | 0 | — | |||||
| Free cash flow | — | (2) | (1) | (2) | (3) | (7) | (9) | (8) | (7) | (8) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 0 | 0 | 1 | 2 | 13 | 3 | (3) | 4 | 0 | ||||
| Total debt | — | — | — | — | 0 | — | — | 0 | — | — | |||||
| Net debt | — | 0 | 0 | 0 | (2) | (14) | (5) | 0 | (4) | (1) | |||||
| Shareholders’ equity | — | 0 | 0 | 1 | 2 | 13 | 3 | (3) | 4 | 1 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (248.28) | (587.67) | (266.08) | (213.54) | (141.86) | (145.64) | (303.88) | (195.05) | (262.55) | ||||
| ROIC | — | (1,141.27) | (2,096,687.50) | (378.06) | (738.82) | 0.00 | 0.00 | 0.00 | (14,412.82) | (24,352.22) | |||||
| ROE | — | 192.33 | 0.00 | (774.81) | (356.08) | (160.92) | (181.47) | (4,408.46) | (743.10) | (373.18) | |||||
Negative figures in brackets.
Charts ten years each
Alzamend Neuro, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACXP Acurx Pharmaceuticals, Inc. | $6.5M | — (loss-making) | — | — | n/m | −2.36% (below 0%: shrinking) | — | 0.00% | Compare |
| TCRT Alaunos Therapeutics, Inc. | $6.4M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | +57.20% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EVGN Evogene Ltd. | $6.3M | — (loss-making) | — (loss-making) | −35.02% (below 0%: shrinking) | n/m | +17.72% (above 0%: growing) | 40.63% | (738.62%) | Compare |
| LEXX Lexaria Bioscience Corp. | $6.3M | — (loss-making) | — (loss-making) | −89.12% (below 0%: shrinking) | n/m | +53.90% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ENVB Enveric Biosciences, Inc. | $6.2M | — (loss-making) | — (loss-making) | −7.28% (below 0%: shrinking) | n/m | −29.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TRAW Traws Pharma, Inc. | $6.2M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −25.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALZN Alzamend Neuro, Inc. | $6.2M | — (loss-making) | — | — | n/m | +51.82% (above 0%: growing) | 0.00% | 0.00% | |
| NRSN NeuroSense Therapeutics Ltd. | $6.0M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | Compare |
| IMNN Imunon, Inc. | $6.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −4.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $6.3M | — | — | −21.15% | — | −3.30% | 20.32% | 0.00% |
Alzamend Neuro, Inc. (ALZN) key facts
- Alzamend Neuro, Inc. (ALZN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ALZN traded at $1.32, a market capitalization of $6.2 million.
- Return on equity was −373.2% and debt-to-equity 0.00.